Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an update.
Ondine Biomedical Inc. has appointed Alan Thomas as the non-Board interim CFO, following the departure of Michael Behlke for personal reasons. Thomas brings over 25 years of financial leadership experience across healthcare and biotechnology sectors, having previously held CFO roles at Maximus Canada Inc. and BC Transit. His expertise in financial strategy and governance is expected to support Ondine’s growth and the expansion of its light-activated antimicrobial technology. This leadership change comes as Ondine is poised for significant development, with its innovative technology gaining traction in key markets.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products in development, including its nasal photodisinfection system, Steriwave®, which is approved in Canada and Europe and undergoing clinical trials in the US. Ondine’s technology targets various medical conditions such as chronic sinusitis and ventilator-associated pneumonia.
Average Trading Volume: 153,767
Technical Sentiment Signal: Sell
Current Market Cap: £39.89M
Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.